Women with familial hypercholesterolemia (FH) are prone to early cardiovascular disease and death. Approximately 1:300 people are affected with FH in Norway. Lipid-lowering medication, with the exception of resins, is contraindicated during pregnancy. Stopping lipid-lowering medication may lead to a 40% to 50% increase in low-density lipoprotein (LDL) cholesterol. In addition, a 30% increase in LDL cholesterol and an approximate doubling in fasting triglycerides can also be expected. Because it is unknown whether FH adversely affects pregnant women and their birth outcomes in clinical terms, we analyzed 2319 births of 1093 women with FH. Firstly, this study shows that women with FH do not have an increased risk for prematurity (birth Ͻ gestational week 37), low birth weight (Ͻ2500 g), or frequency of congenital malformations. The results from the present study may thus be reassuring for FH women in childbearing age and their obstetricians. Secondly, some previous reports suggested that women with elevated cholesterol by itself, without FH, are at risk for adverse pregnancy outcomes. In this view, women with FH represent nature's own experiment to test if elevated LDL cholesterol is responsible for adverse pregnancy outcomes. Data from this study show that a genetically determined elevated LDL cholesterol does not negatively affect pregnancy outcome, and therefore suggest that elevated LDL cholesterol per se may not influence pregnancy outcome. See p 1606.
Cost-Effectiveness of Community-Based Strategies for Blood Pressure Control in a Low-Income Developing Country: Findings From a Cluster-Randomized, Factorial-Controlled Trial
High blood pressure (BP) contributes the greatest attributable risk to mortality worldwide. However, evidence on economically efficient strategies to lower BP from low-and middle-income countries remains scarce. The Control of Blood Pressure and Risk Attenuation (COBRA) trial randomized 1341 hypertensive subjects in 12 randomly selected communities in Karachi, Pakistan, to 3 intervention programs compared with usual care: (1) combined home health education (HHE) by lay health workers plus management by trained general practitioners (GPs); (2) HHE only; and (3) trained GPs only. The HHE intervention was modeled on the existing Lady Health Workers Program in Pakistan and provided education on healthy diet, physical activity, and tobacco cessation in the home setting at 3-month intervals. GP training was an annual 1-day session on optimal hypertension management. Total costs and effects were assessed at baseline and 2 years to estimate incremental costeffectiveness ratios based on (1) intervention cost; (2) cost of physician consultation, medications, diagnostics, changes in lifestyle, and productivity loss; and (3) change in systolic BP. We found that combined HHE plus GP intervention led to the most BP reduction for the cost (incremental cost-effectiveness ratio of $23 per mm Hg reduction in systolic BP compared with usual care) and remained so in 97.7% of 1000 bootstrapped replications. The estimated cost of the combined intervention was $115 per disabilityadjusted life-year averted from the policymakers' perspective and $1226 per disability-adjusted life-year averted from the societal perspective; $0.43 per capita population per year would be needed to scale up the intervention in Pakistan. Thus, the combined intervention of GP training plus HHE intervention could potentially be an effective and affordable strategy for many low-and middle-income countries worldwide that are urgently in need of efforts to prevent and control hypertension. See p 1615.
Blocking of Frizzled Signaling With a Homologous Peptide Fragment of Wnt3a/Wnt5a Reduces Infarct Expansion and Prevents the Development of Heart Failure After Myocardial Infarction
Myocardial infarction is one of the major causes of heart failure. The scar in the infarct area shows a progressive thinning in these patients, causing excessive dilatation of the entire left ventricle, which leads to pump failure. This dilatation can be attributed to the repetitive mechanical strain that the cardiac cycle places on the scar, causing wear of the extracellular matrix in the scar tissue. Previous work from our laboratory and others has highlighted the importance of myofibroblasts in the maintenance of this scar: The smooth musclelike contractile properties of these cells provide a sustained contractile force that is subsequently anchored by the deposition of extracellular matrix. In this article, we propose the targeting of myofibroblasts as a novel therapeutic approach to prevent infarctrelated heart failure. We have shown previously that myofibroblasts in the infarct area express Frizzled receptors. The receptors use Wnt proteins as their endogenous ligands. Here we describe a fragment of Wnt5a, named UM206, that blocks the interaction between Wnt and Frizzled with high affinity. When administered to infarcted mice, UM206 completely prevented heart failure development. Moreover, infarct thinning and left ventricular dilatation were significantly reduced by UM206, which may be explained by a 4-fold increase in myofibroblast numbers in the infarct area. This study shows that Frizzled blockers may be a novel drug class that can prevent heart failure development after myocardial infarction. See p 1626.
Causes of Delay and Associated Mortality in Patients Transferred With ST-Segment-Elevation Myocardial Infarction
Regional ST-segment-elevation myocardial infarction systems are being developed to improve timely access to primary percutaneous coronary intervention (PCI). System delays may diminish the mortality benefit achieved with primary PCI in ST-segment-elevation myocardial infarction patients, but the specific reasons for and clinical impact of delays in patients transferred for PCI are unknown. We report the frequency, magnitude, and clinical impact of specific delays that occur at the referral hospital, during transport, and at the PCI hospital for 2034 patients transferred for PCI in a regional ST-segment-elevation myocardial infarction system. Despite the use of evidence-based strategies to improve treatment times, delays still occurred frequently within the ST-segment-elevation myocardial infarction system. Delays occurred most frequently at the referral hospital, and were most often due to awaiting transport and emergency department delays. Delays occurred less frequently during transport or at the PCI center. Diagnostic dilemmas and nondiagnostic initial ECGs led to delays of the greatest magnitude but had limited or no impact on mortality. Delays caused by out-of-hospital cardiac arrest and/or cardiogenic shock had the highest impact on in-hospital mortality. In these high-risk patients, the delay rarely led to the cardiac arrest or cardiogenic shock; instead, the critical nature of the patient's illness resulted in the delay. These results have implications for the design of regional ST-segment-elevation myocardial infarction systems and may affect the current American 
Inhaled Nitric Oxide Improves Outcomes After Successful Cardiopulmonary Resuscitation in Mice
Sudden cardiac arrest is one of the leading causes of death worldwide. Despite advances in resuscitation techniques, Ͻ8% of the 300 000 adults who experience cardiac arrest in the United States each year survive to hospital discharge, and up to 60% of survivors have long-lasting neurological deficits. Although therapeutic hypothermia has proven effective in clinical studies, no pharmacological agent is available to improve outcome from cardiac arrest. Although originally developed as a selective pulmonary vasodilator, inhaled nitric oxide (NO) has been shown to have systemic effects in a variety of preclinical and clinical studies without causing systemic vasodilation. In the present study, we found that breathing a low concentration of NO starting 1 hour after successful cardiopulmonary resuscitation for 23 hours markedly improves long-term neurological and cardiac outcomes and survival in mice subjected to cardiac arrest and cardiopulmonary resuscitation. The ability of NO breathing to improve outcomes after cardiac arrest when begun after cardiopulmonary resuscitation, if extrapolated to human beings, makes inhaled NO a practical therapeutic approach that can be initiated after patients are transferred to a hospital. Furthermore, because inhaled NO does not cause systemic hypotension, in contrast to systemic NO donors, it is uniquely suited for the treatment of post-cardiac arrest patients in whom blood pressure is often unstable. We anticipate that the established safety profile of NO inhalation will enable the rapid translation of findings in animal models to patients suffering from the post-cardiac arrest syndrome. See p 1645.
Anticoagulation With the Oral Direct Thrombin Inhibitor Dabigatran Does Not Enlarge Hematoma Volume in Experimental Intracerebral Hemorrhage
The direct thrombin inhibitor dabigatran was recently approved for long-term prophylaxis of thrombembolic events in patients with atrial fibrillation. For this indication, the Randomized Evaluation of Long-Term Anticoagulation Therapy (RE-LY) trial revealed a favorable benefit-risk profile for dabigatran compared with that of the gold standard, warfarin. Intracerebral hemorrhage (ICH) is the most feared complication of long-term anticoagulation. Whereas warfarin pretreatment leads to largely increased hematoma volumes and higher mortality rates compared to those of ICH occurring in nonanticoagulated patients, no such data are available for dabigatran anticoagulation. In 2 animal models of ICH, we found no differences in terms of hematoma volume between dabigatran-treated mice and controls, whereas warfarin anticoagulation dramatically worsened ICH volume. On a molecular level, warfarin vastly reduced activity levels of coagulation factors II, VII, IX, and X, but dabigatran reversibly inhibited the active site of factor II only, still allowing sufficient coagulation induction to prevent extensive hematoma enlargement. If confirmed in humans, our findings may represent a significant safety advantage of dabigatran anticoagulation over that of warfarin. Further study is warranted to determine if rapid anticoagulation reversal (eg, by means of prothrombin complex concentrates) is not necessary for ICH occurring during dabigatran treatment. See p 1654.
Adipose Tissue ATP Binding Cassette Transporter A1 Contributes to High-Density Lipoprotein Biogenesis In Vivo
Adipose tissue is a major pool of whole-body free cholesterol (FC) and abundantly expresses ATP binding cassette transporter A 1 (ABCA1), a membrane protein necessary for high-density lipoprotein (HDL) particle formation. Although adipocytes abundantly express ABCA1, their contribution to HDL production in vivo is unknown. Using adipocyte-specific ABCA1 knockout mice, we demonstrate for the first time that adipocytes make nascent, discretesized HDL particles that represent a significant (Ϸ15%) source of plasma HDL. Furthermore, deletion of ABCA1 in adipocytes results in a 2-fold increase in FC content, suggesting that other FC export mechanisms cannot compensate for loss of ABCA1. Adipose tissue ABCA1 expression varies over a 5-fold range among different adipose depots in wild-type mice and is significantly correlated with adipose tissue FC content, suggesting an important role for ABCA1 in adipose tissue FC homeostasis. Because adipocyte FC content increases with obesity and adipocyte hypertrophy, we speculate that ABCA1 is upregulated in adipocytes to maintain optimal FC balance between the lipid droplet and plasma membrane and adipocyte function. Accretion of FC during adipocyte expansion may sequester FC on lipid droplets, shunting it away from ABCA1-mediated HDL particle formation, resulting in decreased plasma HDL concentrations with development of obesity. In contrast, rapid weight loss may result in FC mobilization to the adipocyte plasma membrane, resulting in increased ABCA1-mediated HDL particle formation and increased plasma HDL concentrations. Thus, adipocyte ABCA1 quantitatively contributes to plasma HDL levels and may be critical as a negative regulator of obesity and metabolic syndrome by preventing adipocytes from abnormal FC accumulation and dysfunction. See p 1663.
